ProfileGDS5678 / 1427560_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 44% 44% 34% 44% 44% 45% 56% 55% 54% 46% 47% 44% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0705644
GSM967853U87-EV human glioblastoma xenograft - Control 23.0160944
GSM967854U87-EV human glioblastoma xenograft - Control 33.0321244
GSM967855U87-EV human glioblastoma xenograft - Control 42.7111734
GSM967856U87-EV human glioblastoma xenograft - Control 52.9728944
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1083944
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1200445
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4252256
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3601455
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3332454
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0689746
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0692447
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0359144
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5676960